Scoop: Calling off an IPO, a cancer and Covid-19 vaccine maker raises a Series C

Kyle LaHucik

Associate Editor

An oncology and Covid-19 biotech led by a former Flagship Pioneering venture partner is close to wrapping up its Series C after a bear market shut the doors to a planned IPO, Endpoints News has learned.

Elicio Therapeutics has secured $37 million of its planned $40 million Series C, the company confirmed in an email to Endpoints. The Boston biotech had sought to list on Nasdaq as ELTX, with a draft registration statement filed in April 2021 and subsequent SEC filings showing ambitions to price between $12 to $14 apiece. The offering would’ve brought in about the same amount of capital as Elicio now seeks in its private round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Scoop: Calling off an IPO, a cancer and Covid-19 vaccine maker raises a Series C

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Site Quality Head, Cell & Gene Technology

Lonza

Portsmouth, NH, USA

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Madrigal raises $500M for NASH drug launch, discloses cyberattack

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

Scoop: Call­ing off an IPO, a can­cer and Covid-19 vac­cine mak­er rais­es a Se­ries C

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Lonza

Portsmouth, NH, USA

Scoop: Calling off an IPO, a cancer and Covid-19 vaccine maker raises a Series C